1. Home
  2. GAM vs NUVB Comparison

GAM vs NUVB Comparison

Compare GAM & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo General American Investors Inc.

GAM

General American Investors Inc.

HOLD

Current Price

$64.11

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.11

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAM
NUVB
Founded
1927
2018
Country
United States
United States
Employees
N/A
298
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GAM
NUVB
Price
$64.11
$5.11
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.38
AVG Volume (30 Days)
30.0K
2.9M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
5.74%
N/A
EPS Growth
N/A
N/A
EPS
11.67
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$203.82
Revenue Next Year
N/A
$58.18
P/E Ratio
$5.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.73
$1.57
52 Week High
$64.42
$9.75

Technical Indicators

Market Signals
Indicator
GAM
NUVB
Relative Strength Index (RSI) 72.27 62.11
Support Level $62.22 $4.06
Resistance Level $64.28 $5.55
Average True Range (ATR) 0.94 0.24
MACD 0.53 0.11
Stochastic Oscillator 95.52 91.51

Price Performance

Historical Comparison
GAM
NUVB

About GAM General American Investors Inc.

General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: